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Abstract
Introduction: Bone disorders including osteopenia and osteoporosis are a fre-
quent cause of morbidity in sickle-cell disease (SCD). Magnesium (Mg) regu-
lates some biological processes important in bone remodelling. We aimed to
investigate whether serum Mg levels (sMg) may have an impact on bone min-
eral density (BMD) in sickle-cell anaemia (SCA). 
Material and methods: Sixty adults with SCA in steady-state and 20 age- and
race-matched healthy blood donors were included in the study. The BMD was
evaluated with respect to minerals and biochemical indices of bone metabolism.
Multivariate analysis was performed to determine the factors influencing BMD. 
Results: The mean sMg concentration was 0.64 ±0.06 (reference range 0.7-1.2 mmol/l)
for 34% of the population, and 0.86 ±0.08 mmol/l for 66%. There were significant
differences between Mg groups and controls in BMD, phosphorus (PO4), parathy-
roid hormone (PTH) (p = 0.011, p = 0.011 and p = 0.0001 respectively) and osteo-
calcin (OC) (p = 0.030) levels. The sMg was found to be associated positively with
serum calcium (Ca), PTH and OC (r = 0.585; r = 0.436; r = 0.351 respectively, all at 
p < 0.05), and negatively with PO4 (r = –0.312; p < 0.05). Multivariate analysis demon-
strated that only PTH (p < 0.05) was an independent factor for BMD. Moreover, 
it identified sMg, OC, and CTX as independent factors for PTH (all p < 0.05). 
Conclusions: These results indicate that serum Mg may be a co-contributing
factor in causing low BMD. However, other possible aetiologies including
decreased PTH and increased bone turnover certainly play a role. Based on the
present data, it is prudent to monitor sMg routinely in this patient population
and treat the condition whenever possible. 
Key words: sickle-cell anaemia, magnesium, calcium, bone mineral density, parathy-
roid hormone, osteoporosis, bone turnover.
Introduction
Sickle-cell disease (SCD) is an autosomal recessive genetic disease with
an increase in the adhesion of sickled erythrocytes, and it is a potential
cause of vaso-occlusive episodes, which are related to clinical manifesta-
tions, morbidity and mortality [1, 2]. The SCA often coincides with osteo-
porosis or osteopenia in children and young adults [3]. Accumulated evi-
dence suggests that tissue injury and adverse effects on bone are usually
produced by increased erythropoiesis and hypoxic conditions secondary
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to the obstruction of blood vessels by sickled ery-
throcytes [4, 5]. 
Magnesium (Mg) plays an important role in the
pathophysiology of erythrocyte sickling in SCA [6].
Magnesium has also been shown to slow clotting
time [7, 8], which might reduce vascular blockage
and improve blood flow in SCD. Clinical studies
showed that Mg deficiency, which is partially due
to increased urinary Mg excretion [9], induces dehy-
dration and morphological abnormalities in ery-
throcytes, promotes vasoconstriction and enhances
vascular endothelial injury, leading to hypoxia in
multiple organs including the osseous tissue [10].
Additionally, Mg regulates biological processes
important in bone remodelling such as calcium
absorption, parathyroid hormone (PTH) secretion,
osteoblast adhesion and bone formation [11-13].
The Mg deficiency produces hormonal and skeletal
disturbances that have been associated with
a number of bone disorders including osteoporosis
[14, 15]. This has been supported by experimental
magnesium deficiency studies showing that insuf-
ficient dietary Mg intake increased osteoclast num-
ber, and bone loss in laboratory animals [16].
This does not appear to have been studied in
patients with sickle-cell anaemia and this prompt-
ed us to assess the prevalence of Mg deficiency in
a group of adult patients with SCD, and to analyse
the relationships between bone turnover markers
with serum Mg to determine the role of Mg in the
pathogenesis of bone changes seen in SCD. 
Material and methods
Subjects 
Adult patients with steady state SCD within the
age range 20-40 years visiting the outpatient clinic
of the university hospital were asked to participate
in the study. Twenty age and race matched HbAA
healthy blood donors were enrolled in the study as
the control group. Ethical approval was obtained
from the research and scientific committee of the
university. Informed consent was obtained from all
participants after explanation of the nature of the
study. History was taken and clinical examination
was done and followed by appropriate investiga-
tions to rule out any secondary disorders that might
be causing osteoporosis. Patients who were on
steroids, had anorexia nervosa, hyperthyroidism,
chronic obstructive pulmonary disease, liver disease,
inflammatory bowel disease, or had deranged renal
functions (serum creatinine > 2.5 mg/dl) were
excluded from the study. 
Bone mineral density measurements
Bone mineral density (BMD) and T-score analy-
ses were done at lumbar spine L2, lumbar spine L4
and total body BMD twice by dual-energy X-ray
absorptiometry (DXA) imaging (Hologic QDR 2000,
Bedford, MA). T-scores are standard deviations of
patient BMD compared with BMD of young,
healthy, sex-matched adult controls. T-score values
were calculated based on data of young adults aged
20-40 years [17]. Cases studied were classified as
osteoporosis when T-score was ≤ 2.5 and osteope-
nia when T-score was between –1.0 and –2.5 at one
or more anatomical sites, consistent with WHO cri-
teria [18].
Biochemical tests
All blood samples were collected at 10 am after
overnight fasting. Serum samples were separated
by centrifugation at 3000 rpm for 10 min, and then
were stored in the freezer at –80°C until analysis.
Serum calcium (Ca), magnesium (Mg) and phos-
phate (PO4) were measured using an endpoint
assay in a Dade Behring Dimension RxL clinical
chemistry system (Dade Behring; Germany) using
standard procedures [19]. Total calcium concentra-
tion was adjusted for serum albumin. The labora-
tory reference ranges are 2.2-2.6 mmol/l for Ca, 
0.8-1.2 mmol/l for Mg, and 1.0-1.4 mmol/l for PO4.
Intact serum parathyroid hormone (iPTH) levels
were measured by electrochemiluminescence
immunoassay (Roche Diagnostics, Germany) [20].
The reference range for iPTH was 15-65 pg/ml 
(1.6-6.9 pmol/l), with analytical sensitivity of < 0.1
pmol/l and intra- and inter-assay CV (coefficient of
variation) values less than 5% and 7%, respective-
ly. Serum b-ALP was detected using an EIA kit
(OSTASE® Bone Specific Alkaline Phosphatase EIA,
Immunodiagnostic Systems Inc, Fountain Hills, AZ,
USA) [21]. Analytical sensitivity for the b-ALP assay
was < 1 U/l (reference range between 50 U/l and
136 U/l) with an intra- and inter-assay variability
lower than 10.1% and 10%, respectively. Serum
intact OC level was assessed by a solid-phase
enzyme-amplified sensitivity immunoassay kit
(hOST-EASIA; BioSource Europe S.A., Nivelles, Bel-
gium). This immunoassay is specific for measure-
ment of intact form of osteocalcin with proven
absence of cross reactivity with other osteocalcin
fragments [22]. Analytical sensitivity was < 0.4 ng/
ml (reference range between 6.8 ng/ml and 32.2 ng/
ml) with intra- and inter-assay CV values of 5.2%
and 6.7% respectively. The serum marker of bone
resorption C-terminal telopeptide of type-I collagen
(CTx) was measured by a two-site ELISA (Serum
Crosslaps one-step; Osteometer Biotech, A/S, Den-
mark). The reference range is between 0.13 ng/ml
and 4.1 ng/ml and intra- and inter-assay CV of the
assay is 5.2% and 6.7%. Serum N-terminal telopep-
tide of type-I collagen (NTx), a specific biochemical
indicator of bone resorption, was measured using
an enzyme immunoassay (Osteomark® Wampole
Laboratories Inc., Princeton, NJ, USA) with detec-
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tion limit of 2.5 nM bone collagen equivalent (BCE)
(reference range: 10 nM to 60 nM BCE), and CV
equal to 4.6% [22]. 
Statistical analysis 
Results were expressed as mean ± standard
deviation. χ2 tests, ANOVA, and non-parametric
tests for trend were used, as appropriate, to com-
pare the proportion of patients with specified clin-
ical characteristics. When significant differences
were observed in ANOVA, Bonferroni post-hoc test-
ing was done to identify differences between
groups. Correlation analysis was done using linear
regression and Pearson’s correlation coefficient.
Statistical significance was defined by a p < 0.05.
All statistical tests were two-tailed. A sample size
analysis demonstrated that 19 subjects would be
required in each group to detect a statistically sig-
nificant (p < 0.05) difference of 0.05 in serum mag-
nesium level between groups (SD, 0.05; power,
88%). Calculations were done using SPSS for Win-
dows (release 13.0, 2004; SPSS Inc., Chicago, IL). 
Results
Sixty SCA patients, confirmed by previous
haemoglobin electrophoresis and/or HPLC, were
included in the study. The mean age of patients was
24.64 (±4.26) years (34 females and 26 males). The
control group included 20 age-matched (26.73 ±5.84
years old) subjects (22 females and 18 males). The
χ2 analysis showed no significant differences
between patients and control groups regarding age
(χ2 = 0.33, p > 0.05) or sex (χ2 = 0.64, p > 0.05).
According to WHO criteria using T scores, 
43 patients (71%) were osteoporotic or osteopenic
at least in one of the three studied anatomical loca-
tions. The SCA patients showed significantly lower
BMD T-score at L2, L4 and WB-BMD in comparison
with controls (p = 0.002; p = 0.035; and p = 0.008
respectively). There was a significant decrease of
serum Ca (p = 0.022) and serum PTH (p < 0.0001),
and a significant increase in serum PO4 (p = 0.006)
in the patient group compared to the control group.
Significant increases in b-ALP, OC, and CTX levels
were also found in SCA patients compared to con-
trols (p = 0.021, p = 0.001, p = 0.017 respectively);
however, serum NTX demonstrated no significant
change between groups (Table I).
To determine the impact of Mg deficiency in
this group of SCA patients on other minerals, hor-
monal, and bone turnover markers, patients were
divided according to their serum Mg concentra-
tions into hypomagnesaemic (Mg < 0.7 mmol/l)
and normomagnesaemic (Mg ≥ 0.7 mmol/l), and
these parameters were compared to those of con-
trols. Twenty patients (33.3%) had serum Mg lev-
els lower than the normal range (0.7-1.2 mmol/l).
These hypo-Mg patients had significantly lower
BMD and T-score at all evaluated sites (L2, L4, 
and WB) than norm-Mg patients and controls (all
p < 0.05) (Figure 1). Hypo-Mg patients showed low-
er Ca (p < 0.001) and PTH (p < 0.001) concentra-
tions compared with norm-Mg patients and con-
trols. Analyses of biochemical bone marker data
showed that hypo-Mg SCA patients had signifi-
cantly higher PO4, b-ALP and OC concentrations
in comparison to norm-Mg and controls (p < 0.05;
p < 0.05 respectively). Serum CTx, and NTx con-
centrations were not significantly different
between studied groups by ANOVA analysis; how-
ever, CTX levels were significantly higher in the
hypo-Mg than the norm-Mg group according to
the post-hoc Bonferroni test (p < 0.05).
Table III presents the univariate Pearson corre-
lations between the studied parameters. Serum Mg
showed significant positive correlations with Ca 
(r = 0.736, p < 0.000), PTH (r = 0.446, p < 0.05), and
OC (r = 0.358, p < 0.05), and a significant negative
Parameter SCD Group Control group  Value of p
(n = 60) (n = 20)
Age [years] 22.37 ±7.40 22.87 ±4.91 0.631
Mg [mmol/l] 0.74 ±0.14 0.85 ±0.17 0.044
Ca [mmol/l] 2.11 ±0.13 2.36 ±0.19 0.022
PO4 [mmol/l] 1.32 ±0.25 1.14 ±0.23 0.006
PTH [pmol/l] 2.22 ±1.26 4.11 ±1.46 0.0001
b-ALP [U/l] 77.13 ±14.81 59.69 ±12.57 0.021
OC [ng/ml] 56.46 ±5.3 37.88 ±6.53 0.001
CTX [ng/ml] 0.41 ±0.16 0.36 ±0.16 0.017
NTX [ng/ml] 1.06 ±0.41 0.97 ±0.36 0.383
Mean ± SD, Mg – magnesium, Ca – calcium, PO4 – phosphate, 
b-ALP – bone-specific alkaline phosphatase, OC – total osteocalcin,
CTX-I – C-terminal telopeptide of type-I collagen, NTX – N-terminal
telopeptide of type-I collagen
Table I. Characteristics and laboratory data of healthy








Figure 1. Bone mineral density T-score according to
magnesium levels. ANOVA test revealed significant
variation between groups at L2, L4 and WB-BMD 
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correlation with serum PO4 (r = –0.312, p < 0.05).
The BMD showed a significant negative correlation
with phosphorus and osteocalcin (r = –0.397, 
p < 0.05; r = –0.378, p < 0.05 respectively). The PTH
correlated positively with BMD (r = 0.329, p < 0.05),
and Mg (r = 0.446, p < 0.05) and negatively corre-
lated with OC (r = 0.550, p < 0.001) and CTX 
(r = 0.343, p < 0.05). Calcium showed a significant
positive correlation with Mg (r = 0.736, p < 0.001)
and PO4 (r = 0.390, p < 0.05).
Table IV summarizes the multivariate analysis of
relationships between either BMD or PTH with oth-
er studied parameters. To elucidate the significant
determinants of BMD, we performed a multiple
regression analysis that used the serum Ca, PO4,
Mg, PTH, OC, b-ALP, CTX, and NTX as the potential
explanatory variables. It was found that PTH was
the only independent determinant of BMD 
(p = 0.039). Multiple linear regression analysis also
showed Mg, OC and CTX as independent determi-
nants of PTH (all p < 0.05).
aHypo-Mg – serum Mg < 0.7 mmol/l, bNorm-Mg – serum Mg > 0.7 mmol/l, cp < 0.05 in comparison to controls, dp < 0.05 in comparison to hyper-
Mg group
Parameter SCD patients Control group ANOVA
Hypo-Mga (n = 20) Norm-Mgb (n = 40)
(n = 20)
FS ig.
Age [years] 23.40 ±3.58 21.40 ±6.09 22.87 ±4.91 1.156 0.506
Mg [mmol/l] 0.64 ±0.06c,d 0.86 ±0.08 0.85 ±0.17 17.669 0.0001
Ca [mmol/l] 2.04 ±0.34c,d 2.33 ±0.25 2.36 ±0.19 1.716 0.197
PO4 [mmol/l] 1.23 ±0.32 1.28 ±0.27 1.14 ±0.23 4.963 0.011
PTH [ng/l] 2.22 ±0.95 2.20 ±1.34 4.11 ±1.46 8.604 0.001
b-ALP [U/l] 66.82 ±11.41 81.10 ±13.91 59.69 ±12.57 5.210 0.011
OC [ng/ml] 47.40 ±7.92 60.07 ±13.75 37.88 ±6.53 9.543 0.001
CTx [ng/ml] 0.36 ±0.07c 0.43 ±0.18 0.36 ±0.16 1.180 0.120
NTx (nM BCE) 0.92 ±0.43 1.15 ±0.38 0.97 ±0.36 1.069 0.355
Table II. Comparison of studied parameters between controls and sickle-cell patients classified according to mag-
nesium status
aPearson correlation coefficient, bSignificant correlation (2-tailed)
Parameter BMD PTH Ca Mg
ra Value of pr Value of pr Value of pr Value of p
BMD 1.000 – 0.329b 0.042 0.211 0.300 0.209 0.286
PTH 0.329b 0.042 1.000 – 0.231 0.247 0.446b 0.022
Ca 0.211 0.300 0.231 0.247 1.000 – 0.736b 0.0001
Mg 0.209 0.286 0.446b 0.022 0.736b 0.000 1.000 –
PO4 –0.397b 0.030 0.043 0.828 0.390b 0.032 –0.342b –0.022
b-ALP 0.010 0.957 0.152 0.441 0.269 0.167 0.049 0.641
OC –0.378b 0.044 –0.550b 0.002 0.060 0.761 0.358b 0.031
CTX –0.289 0.122 –0.379b 0.037 –0.135 0.493 0.081 0.748
NTX –0.097 0.610 0.083 0.674 0.268 0.168 0.103 0.631
Table III. Univariate analyses of relationships between Mg and other markers of bone metabolism 
aDependent variable: BMD, predictor in the model: PTH; bdependent
variable: PTH, predictors in the model: osteocalcin, magnesium, CTX;
csignificant correlation
Parameter          aDependent: BMD bDependent: PTH
β Value of p β Value of p
Coefficient Coefficient
BMD – – 0.145 0.373
PTH 0.413c 0.039 – –
Ca –0.055 0.792 –0.062 0.784
Mg 0.161 0.457 0.397c 0.012
PO4 –0.288 0.133 –0.123 0.407
OC –0.123 0.601 0.403c 0.013
b-ALP –0.026 0.895 0.013 0.94
CTX –0.131 0.553 0.399c 0.013
NTX –0.13 0.508 0.039 0.806
Age 0.079 0.662 –0.016 0.918
Table IV. Multivariate analysis of the relationships
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Discussion
In the present study, patients with SCD showed
significantly lower BMD concentration at L2, L4 and
WB-BMD (all p < 0.05) than the control group. Fur-
thermore, 30% of the patients were found to be
osteopenic and 50% osteoporotic based on T-scores
of the patients according to WHO guidelines. These
results are accompanied by a significant reduction
in PTH and serum Ca concentrations and increased
concentration of bone turnover parameters (OC, 
b-ALP and CTX). These results are in accordance
with those of previous literature [1, 23], and sug-
gest a relation between low BMD and increased
bone turnover, as previously reported [24].
It has been suggested that Mg deficiency may
have a role in the development of osteoporosis [25-
27]. We therefore investigated whether alterations
in sMg may have a role in the pathogenesis of bone
changes seen in sickle-cell anaemia. In the present
study, Mg levels were lower than the normal range
(0.7-1.2 mmol/l) in 34% of SCA patients. These
patients showed significantly lower BMD values
and T-score than norm-Mg patients and controls.
These findings suggest that Mg deficiency may
have a role in the decreased BMD found in our
group of patients with SCA. 
We then studied the inter-relationships between
sMg and bone turnover parameters OC, b-ALP, CTX
and NTX. Osteocalcin and b-ALP are phenotypic
markers for terminally differentiated osteoblasts
and early-stage differentiated osteoblasts, respec-
tively [28]. We found that b-ALP and OC are
increased both in hypo- and norm-Mg patients
compared with controls. These findings are in agree-
ment with previous studies reporting accelerated
bone turnover in SCA patients [29]. In addition, we
found that CTX levels are increased significantly in
hypomagnesaemic SCA patients compared to the
control group, which reflects the increased bone
resorption. Moreover, CTX was found to be nega-
tively correlated with PTH by univariate correlation
analysis, and an independent negative determinant
of PTH by stepwise multiple regression analysis. 
The PTH is very important for skeletal health. It
is synthesized and secreted by the chief cells of the
parathyroid glands and is the principal hormone
responsible for calcium homeostasis [30]. We fur-
ther found that the hypo-Mg group had significantly
lower PTH levels than either norm-Mg or controls,
and that serum Mg correlated positively with serum
PTH. These patients showed significantly reduced
BMD. In addition, multivariate analysis identified
PTH as the only predictive factor for BMD. These
data suggest that a blunted PTH response in hypo-
Mg patients may be the causative factor for BMD
reduction in SCD. These results are supported by
previous studies which suggested that Mg defi-
ciency causes impairment of PTH release from the
parathyroid and the refractoriness of bone and kid-
ney to the hormone, which may lead to the sup-
pression of bone remodelling [14, 25, 31, 32]. 
The reciprocal relationship between Mg and PTH
is well documented [14]. Hypomagnesaemia ap  -
pears to blunt the hypocalcaemic release of PTH [31],
through the intermediary action of cAMP [33]. 
Magnesium is also required for the sensitivity of
the target tissues to PTH and vitamin D metabo-
lites [34, 35]. On the other hand, PTH has profound
effects on Mg reabsorption in the kidney and gut
and release from bone [36].
Another effect of PTH on the kidney is to stim-
ulate loss of phosphate ions in urine by reducing
the reabsorption of phosphate from the proximal
tubule [37]. In the present study we found that PTH
correlates negatively with PO4 (r = –0.321, p < 0.031).
Therefore, the decrease in PTH may explain the ele-
vated serum PO4 observed in these patients. It has
been reported that modest increases in serum PO4
levels significantly affect red cell metabolism,
increase 2,3 diphosphoglycerate (DPG) levels, and
cause decreased affinity of oxygen for haemoglo-
bin. Such changes could lead to increased intravas-
cular sickling and blood flow abnormalities [38],
which have been associated with osteoporosis [23].
Moreover, low levels of total magnesium in sickle-
cell erythrocytes have been linked to increased sick-
ling due to cell dehydration [39]. In the present
study, PO4 was found to be negatively correlated
with serum magnesium (r = –0.342, p < 0.022).
These data suggest that increased serum PO4 along
with decreased serum Mg could represent addi-
tional pathogenic mechanisms contributing, in
these cases, to low BMD.
In conclusion, we identified a group of SCD
patients with reduced serum Mg levels, who had
significantly lower BMD than their counterparts
with normal Mg concentrations, suggesting that
serum Mg may play an important role in bone
metabolism through its association with PTH, OC
and PO4, and may provide additional information
for the pathogenesis of bone loss in this disease.
Finally, the present data warrant further investiga-
tion to determine whether serum Ca/PO4 and PTH
values normalize in SCA patients with Mg repletion
in a prospective way, which will be an important
and cost-effective intervention in this group of
patients.
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